These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21914964)

  • 1. Metabolism and pharmacokinetic studies of JPH203, an L-amino acid transporter 1 (LAT1) selective compound.
    Wempe MF; Rice PJ; Lightner JW; Jutabha P; Hayashi M; Anzai N; Wakui S; Kusuhara H; Sugiyama Y; Endou H
    Drug Metab Pharmacokinet; 2012; 27(1):155-61. PubMed ID: 21914964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203.
    Toyoshima J; Kusuhara H; Wempe MF; Endou H; Sugiyama Y
    J Pharm Sci; 2013 Sep; 102(9):3228-38. PubMed ID: 23712732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors.
    Okano N; Naruge D; Kawai K; Kobayashi T; Nagashima F; Endou H; Furuse J
    Invest New Drugs; 2020 Oct; 38(5):1495-1506. PubMed ID: 32198649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells.
    Yun DW; Lee SA; Park MG; Kim JS; Yu SK; Park MR; Kim SG; Oh JS; Kim CS; Kim HJ; Kim JS; Chun HS; Kanai Y; Endou H; Wempe MF; Kim DK
    J Pharmacol Sci; 2014; 124(2):208-17. PubMed ID: 24492461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
    Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
    Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment.
    Yothaisong S; Dokduang H; Anzai N; Hayashi K; Namwat N; Yongvanit P; Sangkhamanon S; Jutabha P; Endou H; Loilome W
    Tumour Biol; 2017 Mar; 39(3):1010428317694545. PubMed ID: 28347255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function.
    Okunushi K; Furihata T; Morio H; Muto Y; Higuchi K; Kaneko M; Otsuka Y; Ohno Y; Watanabe Y; Reien Y; Nakagawa K; Sakamoto S; Wakashin H; Shimojo N; Anzai N
    J Pharmacol Sci; 2020 Sep; 144(1):16-22. PubMed ID: 32653341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203.
    Muto Y; Furihata T; Kaneko M; Higuchi K; Okunushi K; Morio H; Reien Y; Uesato M; Matsubara H; Anzai N
    Anticancer Res; 2019 Jan; 39(1):159-165. PubMed ID: 30591453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity.
    Rii J; Sakamoto S; Mizokami A; Xu M; Fujimoto A; Saito S; Koike H; Tamura T; Arai T; Yamada Y; Goto Y; Sazuka T; Imamura Y; Suzuki K; Kanai Y; Anzai N; Ichikawa T
    Cancer Sci; 2024 Mar; 115(3):937-953. PubMed ID: 38186218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.
    Ueno S; Kimura T; Yamaga T; Kawada A; Ochiai T; Endou H; Sakurai H
    J Pharmacol Sci; 2016 Jun; 131(2):110-7. PubMed ID: 27262901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker Analyses in Patients With Advanced Solid Tumors Treated With the LAT1 Inhibitor JPH203.
    Okano N; Hana K; Naruge D; Kawai K; Kobayashi T; Nagashima F; Endou H; Furuse J
    In Vivo; 2020; 34(5):2595-2606. PubMed ID: 32871789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth.
    Oda K; Hosoda N; Endo H; Saito K; Tsujihara K; Yamamura M; Sakata T; Anzai N; Wempe MF; Kanai Y; Endou H
    Cancer Sci; 2010 Jan; 101(1):173-9. PubMed ID: 19900191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
    Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
    Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of CTH expression in response to amino acid starvation confers resistance to anti-LAT1 therapy in MDA-MB-231 cells.
    Yamaga T; Suehiro J; Wada Y; Sakurai H
    Sci Rep; 2022 Jan; 12(1):1021. PubMed ID: 35046465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.
    Maimaiti M; Sakamoto S; Yamada Y; Sugiura M; Rii J; Takeuchi N; Imamura Y; Furihata T; Ando K; Higuchi K; Xu M; Sazuka T; Nakamura K; Kaneda A; Kanai Y; Kyprianou N; Ikehara Y; Anzai N; Ichikawa T
    Sci Rep; 2020 Jan; 10(1):1292. PubMed ID: 31992742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
    Valles B; Schiller CD; Coassolo P; De Sousa G; Wyss R; Jaeck D; Viger-Chougnet A; Rahmani R
    Drug Metab Dispos; 1995 Oct; 23(10):1051-7. PubMed ID: 8654192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.
    Wiriyasermkul P; Nagamori S; Tominaga H; Oriuchi N; Kaira K; Nakao H; Kitashoji T; Ohgaki R; Tanaka H; Endou H; Endo K; Sakurai H; Kanai Y
    J Nucl Med; 2012 Aug; 53(8):1253-61. PubMed ID: 22743251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines.
    Yanagida O; Kanai Y; Chairoungdua A; Kim DK; Segawa H; Nii T; Cha SH; Matsuo H; Fukushima J; Fukasawa Y; Tani Y; Taketani Y; Uchino H; Kim JY; Inatomi J; Okayasu I; Miyamoto K; Takeda E; Goya T; Endou H
    Biochim Biophys Acta; 2001 Oct; 1514(2):291-302. PubMed ID: 11557028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells.
    Choi DW; Kim DK; Kanai Y; Wempe MF; Endou H; Kim JK
    Korean J Physiol Pharmacol; 2017 Nov; 21(6):599-607. PubMed ID: 29200902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.